(R)-4-(4,4-diethyl-2-imino-6-oxotetrahydropyrimidin-1(2H)-yl)-N-((S)-2,3,4,5-tetrahydrobenzo[b]oxepin-5-yl)chromane-6-carboxamide

ID: ALA5207556

Chembl Id: CHEMBL5207556

PubChem CID: 168297930

Max Phase: Preclinical

Molecular Formula: C28H34N4O4

Molecular Weight: 490.60

Associated Items:

Names and Identifiers

Canonical SMILES:  CCC1(CC)CC(=O)N([C@@H]2CCOc3ccc(C(=O)N[C@H]4CCCOc5ccccc54)cc32)C(=N)N1

Standard InChI:  InChI=1S/C28H34N4O4/c1-3-28(4-2)17-25(33)32(27(29)31-28)22-13-15-36-24-12-11-18(16-20(22)24)26(34)30-21-9-7-14-35-23-10-6-5-8-19(21)23/h5-6,8,10-12,16,21-22H,3-4,7,9,13-15,17H2,1-2H3,(H2,29,31)(H,30,34)/t21-,22+/m0/s1

Standard InChI Key:  CTDJSVJRZFOZMC-FCHUYYIVSA-N

Alternative Forms

  1. Parent:

    ALA5207556

    ---

Associated Targets(non-human)

Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PMX Plasmepsin X (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PMIX Plasmepsin IX (10 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 490.60Molecular Weight (Monoisotopic): 490.2580AlogP: 4.47#Rotatable Bonds: 5
Polar Surface Area: 103.75Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 5.19CX LogP: 3.50CX LogD: 3.50
Aromatic Rings: 2Heavy Atoms: 36QED Weighted: 0.57Np Likeness Score: -0.40

References

1. de Lera Ruiz M, Favuzza P, Guo Z, Zhao L, Hu B, Lei Z, Zhan D, Murgolo N, Boyce CW, Vavrek M, Thompson J, Ngo A, Jarman KE, Robbins J, Boddey J, Sleebs BE, Lowes KN, Cowman AF, Olsen DB, McCauley JA..  (2022)  The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.,  13  (11.0): [PMID:36385924] [10.1021/acsmedchemlett.2c00355]

Source